Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148997 | 0.98 | AURKB (0.36) | MERTKAURKBPDE3BPDE3A | |
| SCHEMBL2973757 | 0.93 | MERTK (0.35) | MERTK | |
| SCHEMBL2973767 | 0.93 | MERTK (0.35) | MERTK | |
| Trifluoroacetic Acid SCHEMBL2985389 | 0.88 | CHRNB2 (0.37) | MERTK | |
| SCHEMBL2980471 | 0.87 | PDE3B (0.40) | PDE3BPDE3A | |
| SCHEMBL2973307 | 0.87 | PDE3B (0.41) | AURKBPDE3BPDE3A | |
| SCHEMBL2987877 | 0.87 | PDE3B (0.31) | PDE3BPDE3A | |
| SCHEMBL2980391 | 0.87 | PDE3B (0.42) | AURKBPDE3BPDE3A | |
| SCHEMBL2983812 | 0.86 | PDE3B (0.36) | PDE3BPDE3A | |
| SCHEMBL2983864 | 0.85 | PDE3B (0.36) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | MERTK 1248/4885AURKB 4412/4885PDE3B 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.